Stockreport

Immatics Announces Full Year 2023 Financial Results and Corporate Update [Yahoo! Finance]

Immatics N.V. - Ordinary Shares  (IMTX) 
PDF median duration of response not reached at median follow-up of 14.4 months; IMA203 was well tolerated Registration-enabling randomized Phase 2/3 trial for ACTengine® I [Read more]